Edition:
India

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

5.60USD
19 Jul 2019
Change (% chg)

$0.12 (+2.19%)
Prev Close
$5.48
Open
$5.49
Day's High
$5.66
Day's Low
$5.42
Volume
16,951
Avg. Vol
44,903
52-wk High
$17.39
52-wk Low
$3.25

Latest Key Developments (Source: Significant Developments)

AC Immune Says Douglas Williams Elected As Chairman
Friday, 28 Jun 2019 

June 28 (Reuters) - AC Immune SA ::AC IMMUNE ANNOUNCES ELECTION OF NEW CHAIRMAN OF THE BOARD AT ANNUAL GENERAL MEETING.AC IMMUNE SA - HAVE ELECTED DOUGLAS WILLIAMS AS CHAIRMAN OF BOARD AT TODAY'S ANNUAL GENERAL MEETING.AC IMMUNE SA - AT AGM HELD IN LAUSANNE, SHAREHOLDERS ALSO ELECTED MARTIN VELASCO, PREVIOUSLY CHAIRMAN, AS VICE-CHAIRMAN OF BOARD.AC IMMUNE SA - DETLEV RIESNER HAS RETIRED AND DID NOT STAND FOR RE-ELECTION..  Full Article

AC Immune QTRLY Earnings Per Share CHF 0.91
Wednesday, 15 May 2019 

May 15 (Reuters) - AC Immune SA ::AC IMMUNE REPORTS Q1 2019 FINANCIAL RESULTS AND BUSINESS UPDATE.QTRLY TOTAL REVENUE CHF75 MILLION VERSUS CHF1.5 MILLION.QTRLY EARNINGS PER SHARE CHF 0.91.QTRLY ADJUSTED EARNINGS PER SHARE CHF 0.85.  Full Article

AC Immune Sees 2019 Total Operating Expenses To Range Between CHF 65−80 Mln
Thursday, 21 Mar 2019 

March 21 (Reuters) - AC Immune SA ::AC IMMUNE REPORTS FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.SEES 2019 TOTAL OPERATING EXPENSES TO RANGE BETWEEN CHF 65−80 MILLION, UP FROM CHF 56.8 MILLION IN 2018.CHF 300 MILLION CASH POSITION AS OF Q1 2019 FUNDS OPERATIONS THROUGH Q3 2023.  Full Article

AC Immune And Wuxi Biologics To Establish An Exclusive Strategic Partnership
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - AC Immune SA ::AC IMMUNE AND WUXI BIOLOGICS TO ESTABLISH AN EXCLUSIVE STRATEGIC PARTNERSHIP.WUXI BIOLOGICS WOULD BECOME A PREFERRED PARTNER OF AC IMMUNE FOR BIOPROCESS DEVELOPMENT.WUXI BIOLOGICS TO BECOME A PREFERRED PARTNER FOR BIOPROCESS DEVELOPMENT AND MANUFACTURING.AC IMMUNE TO GAIN ACCESS TO WUXI BIOLOGICS' PROPRIETARY DISCOVERY PLATFORMS INCLUDING WUXIBODY(TM) PLATFORM.  Full Article

AC Immune SA reports quarterly ‍loss per share CHF 0.15
Monday, 13 Nov 2017 

Nov 13 (Reuters) - AC Immune SA ::AC Immune SA reports third quarter 2017 financial results and corporate update.AC Immune SA qtrly ‍loss per share CHF 0.15 .Says qtrly adjusted loss per share CHF ‍0.16​.  Full Article

AC Immune to get milestone payment for Alzheimer drug
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - AC Immune Ltd :Says to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's disease ‍​.Says upon the dosing of the first patient in the phase 2 clinical trial, AC Immune becomes eligible to receive a milestone payment of CHF 14 million, which is expected to be paid in the fourth quarter of 2017‍​.Says this will be the third milestone payment under the 2012 strategic collaboration and licensing agreement with Genentech.  Full Article

AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for alzheimer's disease
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ac Immune Ltd :AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's Disease.Ac Immune - ‍upon dosing of first patient in phase 2 trial of RO7105705​, co becomes eligible to get milestone payment of CHF 14 million, expected in Q4 2017.  Full Article

AC Immune completes recruitment for low-dose cohort in world's first clinical trial for Anti-Abeta Vaccine
Tuesday, 12 Sep 2017 

Sept 12 (Reuters) - Ac Immune Ltd :AC Immune completes recruitment for low-dose Cohort in world's first clinical trial for Anti-Abeta Vaccine targeting alzheimer's disease-like characteristics in individuals with down syndrome.  Full Article

AC Immune reports Q2 ‍loss per share CHF 0.22​
Wednesday, 9 Aug 2017 

Aug 9 (Reuters) - Ac Immune Ltd :AC Immune reports second quarter 2017 financial results.Q2 revenue chf 800,000.AC Immune Ltd qtrly ‍loss per share chf 0.22​.AC Immune Ltd qtrly adjusted ‍loss per share chf 0.14​.Q2 earnings per share view chf -0.16 -- Thomson Reuters I/B/E/S.AC Immune Ltd qtrly revenues chf 800,000 versus chf 19.9 mln‍​.  Full Article

UPDATE 2-Roche sees 2019 sales, profit rise despite competition from copies

* Forecasts new medicines to offset competition (Adds details throughout, comment from CEO)